AtriCure Launches cryoSPHERE MAX Cryoablation Probe

AtriCure has launched its cryoSPHERE MAX cryoablation probe.
 
The company’s new probe features a larger ball tip, which is designed to optimize Cryo Nerve Block (Cryo NB) therapy. It reduces freeze times by 50% compared to AtriCure’s first-generation cryoSPHERE cryoablation probe, and over 30% compared to the cryoSPHERE+ probe.
 
The next-generation device also touts upgrades in insulation, nitrous oxide gas use, tactile tissue feedback, and real-time temperature monitoring. The larger, 10mm ball tip has 60% more surface area than the current cryoSPHERE devices, which improves target tissue coverage, more heat extraction, and larger ice ball formation.
 
cryoNB therapy is an adjunctive, non-pharmacological procedure that uses AtriCure’s cryoICE platform technology to freeze targeted intercostal nerves and temporarily block pain along peripheral nerve pathways. Physicians are using cryoNB therapy as part of their multimodal strategy to provide post-operative pain relief for several months after surgery.
 
“Every second matters in patient care, and the cryoSPHERE MAX optimizes efficiency for patients and surgeons,” said Michael Carrel, president and CEO at AtriCure. “Strengthening our groundbreaking platform of devices for Cryo Nerve Block therapy underscores AtriCure’s commitment to enhancing surgeons’ procedural experience and pursuing better outcomes for patients.”
 
Earlier this month, AtriCure earned CE mark approval for is EnCompass clamp, which lets physicians perform a comprehensive epicardial ablation of the left atrium in a few minutes.